Drug Trial Radar · NCT04270747
A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]
Last checked: Nov 19, 2026Latest source record: Sep 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
576
Actual
Start
Jun 22, 2020
Primary completion
Jul 18, 2022
Study completion Jan 30, 2023
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- Feb 17, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the efficacy and safety of ABP 938 versus Aflibercept (Eylea®) in the treatment of neovascular age-related macular degeneration. Subjects will be randomized in a masked 1:1 ratio to receive 2 mg (0.05 mL) of either ABP 938 (Treatment Group A) or aflibercept (Treatment Group B) administered by intravitreal (IVT) injection.
Conditions
- Neovascular (Wet) Age-related Macular Degeneration (AMD)
Interventions
ABP 938Drug
Subject will receive ABP 938 2 mg (0.05 mL) IVT injection every 4 weeks for the first 3 doses, followed by once every 8 weeks
AfliberceptDrug
Subject will receive aflibercept 2 mg (0.05 mL) IVT injection every 4 weeks for the first 3 doses, followed by once every 8 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change From Baseline in BCVA at Week 8Time frame: Baseline and Week 8
Locations
118 sites in 18 countries. Site status is shown where the registry gives one.
Associated Retina Consultants, Ltd. - Research
Phoenix, Arizona
Retina Consultants of Orange County
Fullerton, California
UCSD Shiley Eye Institute, Jacobs Retina Center
La Jolla, California
Jules Stein Eye Institute, UCLA
Los Angeles, California
Southern California Desert Retina Consultants
Palm Desert, California
Retina Consultants San Diego
Poway, California
Retina Consultants of Southern California
Redlands, California
Retinal Consultants Medical Group, Inc.
Sacramento, California
Orange County Retina Medical Group
Santa Ana, California
Miramar Eye Specialists
Ventura, California
Colorado Retina Associates
Lakewood, Colorado
Retina Group of New England
Waterford, Connecticut
Florida Retina Consultants
Lakeland, Florida
Medeye Associates
Miami, Florida
Center for Retina and Macular Disease
Winter Haven, Florida
Southeast Retina Center
Augusta, Georgia
Georgia Retina, P.C.
Marietta, Georgia
Retina Associates IL
Elmhurst, Illinois
Sabates Eye Center
Leawood, Kansas
Retina Associates New Orleans
Metairie, Louisiana
The Retina Care Center
Baltimore, Maryland
Specialty Eye Institute
Jackson, Michigan
Retina Center
Saint Louis Park, Minnesota
Retina Vitreous Surgeons of Central NY, PC
Liverpool, New York
Macula Care
New York, New York
Ophthalmic Consultants of the Capital Region - Ophthalmology
Troy, New York
Charlotte Eye Ear Nose & Throat Associates, P.A.
Charlotte, North Carolina
Sterling Research Group
Cincinnati, Ohio
Eye Care Specialists
Kingston, Pennsylvania
Charleston Neuroscience Institute
Ladson, South Carolina
Black Hills Regional Eye Institute - Ophthalmology
Rapid City, South Dakota
Retina Research Institute of Texas
Abilene, Texas
Retina Consultants of Texas Research Centers
Bellaire, Texas
Texas Retina Associates
Dallas, Texas
Texas Retina Associates
Fort Worth, Texas
Texas Retina Associates
Fort Worth, Texas
Ophthalmology Associates
Fort Worth, Texas
Premiere Retina Specialists
Midland, Texas
Retina Associates of South Texas, P.A.
San Antonio, Texas
Retina Consultants of Houston
The Woodlands, Texas
Showing 40 of 118 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.